key: cord-0989110-dwgpqzzm
authors: Verkerke, H. P.; Damhorst, G. L.; Graciaa, D.; McLendon, K.; O'Sick, W.; Robichaux, C.; Cheedarla, N.; Potlapalli, S.; Wu, S.-C.; Harrington, K. R. V.; Webster, A.; Kraft, C.; Rostad, C. A.; Waggoner, J.; Gandhi, N.; Guarner, J.; Auld, S.; Neish, A.; Roback, J. D.; Lam, W. A.; Shah, S.; Stowell, S. R.
title: Nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection
date: 2022-01-27
journal: nan
DOI: 10.1101/2022.01.23.22269354
sha: a28a23145b1abd2529773289c9636f645e5ef6c5
doc_id: 989110
cord_uid: dwgpqzzm

Reliable detection of SARS-CoV-2 infection is essential for diagnosis and treatment of disease as well as infection control and prevention during the ongoing COVID-19 pandemic. Existing nucleic acid tests do not reliably distinguish acute from resolved infection, as residual RNA is frequently detected in the absence of replication-competent virus. We hypothesized that viral nucleocapsid in serum or plasma may be a specific biomarker of acute infection that could enhance isolation and treatment strategies at an individualized level. Samples were obtained from a retrospective serological survey using a convenience sampling method from adult inpatient and outpatient encounters from January through March 2021. Samples were categorized along a timeline of infection (e.g. acute, late presenting, convalescent) based on timing of available SARS-CoV-2 testing and symptomatology. Nucleocapsid was quantified by digital immunoassay on the Quanterix HD-X platform. In a large sample of 1860 specimens from 1607 patients, the highest level and frequency of antigenemia were observed in samples obtained during acute SARS-CoV-2 infection. Levels of antigenemia were highest in samples from seronegative individuals and in those with more severe disease. Using ROC analysis, we found that antigenemia exhibited up to 85.8% sensitivity and 98.6% specificity as a biomarker for acute COVID-19. Nucleocapsid antigenemia is a sensitive and specific biomarker for acute SARS-CoV-2 infection and may aid in individualized assessment of SARS-CoV-2 infection resolution or persistence, although interpretation is limited by absence of a diagnostic gold standard for active infection.

Although the standard of care for SARS-CoV-2, reverse transcription polymerase chain reaction 58 (RT-PCR) remains an imperfect diagnostic marker for coronavirus disease 2019 because 59 SARS-CoV-2 RNA commonly persists beyond the period of acute infection [1] [2] [3] . Accordingly, Centers 60 for Disease Control and Prevention (CDC) guidelines do not recommend re-testing most individuals by 61 RT-PCR within 90 days following diagnosis. Instead, isolation guidelines are based on time from 62 symptom onset [4, 5] . This creates a dilemma when screening tests detect SARS-CoV-2 RNA in a patient 63 without well-defined onset or resolution of COVID-like illness. Alternative molecular markers for acute 64 infection are not widely available [6] and low sensitivity respiratory antigen testing may be effectively 65 applied at a population level [7, 8] , but there remains a need for more sensitive and specific diagnostics to 66 provide individualized guidance. 67

The presence of viral nucleocapsid protein in peripheral blood (antigenemia) has been 68 demonstrated in SARS-CoV-1 and SARS-CoV-2 infection [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . A blood-based antigen biomarker may 69 have inherent advantages over upper respiratory tract antigen testing, or biomarkers such as RT-PCR 70 cycle threshold (Ct) value and sub-genomic RNA (sgRNA), because specimen quality and quantity can be 71 standardized. Reports of antigenemia test performance as a diagnostic biomarker are inconsistent, likely 72 due to varying assay composition and inconsistent reference standards as many studies compare against 73 respiratory RT-PCR as a gold standard and fail to account for the persistence of RNA beyond acute 74 infection. 75

In this study, we present evidence from a large serosurvey of adults in inpatient and outpatient 76 settings to explore the hypothesis that nucleocapsid antigenemia is a sensitive and specific marker of 77 acute infection as defined by a clinical timeline. Specifically, each blood sample was categorized through 78 rigorous review of clinical history and respiratory SARS-CoV-2 testing in a schema that assumes a 79 typical course of COVID-19 for all subjects. We find a strong association between acute infection and 80 nucleocapsid antigenemia, which also correlates with serostatus and disease severity. Together our 81 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 findings suggest antigenemia may clarify disease timing and provide needed insight in many clinical 82 settings. 83 84

Clinical specimens 86

We collected a convenience sample of residual plasma, serum, and whole blood specimens from 87 the clinical chemistry laboratory of Emory Medical Laboratories one day per week between January 11, 88 2021 and March 12, 2021. These specimens were originally collected for routine clinical testing from 89 inpatient (medical/surgical wards, intensive care, obstetrics) and outpatient settings (clinics, emergency 90 department, infusion centers, ambulatory surgery). Samples were transferred to a -80C repository after 91 clinical testing was completed, but prior to being discarded. More than one blood sample from the same 92 patient was permitted with a minimum time of five days between samples. This study was approved and 93 granted complete HIPAA and consent waiver by the Emory University Institutional Review Board 94 (STUDY00000510). 95

Nucleocapsid antigenemia was quantified on the Quanterix HD-X platform. Residual serum and 98 plasma samples were thawed once after storage at -80°C and diluted 1 to 3 in assay sample diluent. 99

Diluted samples were then run using the ultrasensitive SIMOA SARS-CoV-2 N Protein Antigen assay on 100 the automated Quanterix HD-X platform (Quanterix, Billerica, MA, USA) which has a validated limit of 101 detection of 0.099 pg/mL in respiratory and saliva samples. Samples with antigen levels too high for the 102 linear range of the assay were further diluted 1 to 20 and re-tested. Final antigen concentrations were 103 determined by interpolation after sigmoidal fitting of duplicate calibration curves run on each test plate. 104 105 Serological Testing 106 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 In-house developed single-dilution serological screening assays for SARS-CoV-2 receptor 107 binding domain (RBD) and nucleocapsid antibodies were used to establish serological status at the time 108 of antigenemia testing. Antibody class-specific RBD serologies were performed as previously described 109 [22] . Nucleocapsid antibody testing was performed using an in-house developed ELISA (supplementary 110 information). 111

Medical record review 113 Patient medical record number was recorded at the time of specimen collection. The Emory 114

Healthcare Clinical Data Warehouse (CDW) was queried for SARS-CoV-2 nucleic acid amplification 115 tests (NAAT), clinical notes, ICD-10 codes, laboratory values, mechanical ventilation, and date of death. 116

All Ct values were obtained directly from reports produced by the manufacturer's software 117 (supplementary information). 118

A COVID-19 status label (positive or negative) and a category (convalescent, late-presenting, 119 acute, pre-COVID, and same-day negative) were assigned to each blood sample based on that patient's 120

(1) SARS-CoV-2 respiratory testing (including NAAT or antigen), (2) date of earliest positive test, and 121

(3) date of symptom onset (Figure 1) . 122

Chart review began with automated review of NAAT results available in the medical record. 123

Blood samples from a patient with a positive NAAT more than fourteen days prior to sample collection 124 were labeled convalescent and no further review of the medical record for categorization purposes was 125 performed. History and physical clinical notes dated within fourteen days before or after the date of the 126 blood sample were then reviewed, if available, for all patients not labeled convalescent. Date of COVID-127 like symptom onset (including fever, fatigue, malaise, myalgia, headache, dyspnea, cough, wheezing, 128 anosmia, ageusia, congestion, rhinorrhea, or diarrhea) and earliest positive SARS-CoV-2 testing (NAAT 129 or antigen) was recorded if these had been described in the history narrative or clinician's assessment and 130 plan. 131 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10. 1101 /2022 The original medical records were then reviewed for all patients (other than those labeled 132 convalescent) with a positive SARS-CoV-2 test who did not yet have date of symptom onset recorded in 133 our data set. The entire medical record was available during this stage, but the reviewer was blinded to 134 antigenemia status which was not considered in labeling of COVID-19 status or category assignment. 135

Given that re-infection with SARS-CoV-2 was rare at the time of this study [23], our approach 136 assumed that no re-infection events were captured in our sample set, which spanned 3 months. Patients 137 without any record of SARS-CoV-2 testing were excluded from analysis. Further detail is provided in 138

Supplementary Information. 139 140

Data obtained during specimen collection were stored in Microsoft Excel. CDW reports were 142 provided in .csv format. All data were then imported into MATLAB (The MathWorks, Inc.) for analysis. 143

Wilcoxon rank-sum test was used for comparisons. 144 145

Specimens & COVID-19 status assignments 147 2,498 serum and plasma samples were targeted for evaluation during the study period ( Figure  148 1B). Eleven samples were not evaluated for antigenemia due to pre-analytical factors such as insufficient 149 sample volume. 2,487 samples were available for quantification of antigenemia, of which 255 (10.2%) 150 exhibited detectable nucleocapsid. 115 of 2,487 were excluded due to lack of patient identifiers and five 151 additional samples were excluded as they had been collected on the same day as another blood sample 152 from a single patient. Clinical data were examined for the remaining 2,367 samples from 2,101 unique 153 patients ( Table 1) . 507 of 2,367 samples were excluded because of no record of SARS-CoV-2 testing, 154 and 11 of these 507 (2.1%) had detectable antigenemia. 155

The remaining 1,860 samples from 1,607 patients had SARS-CoV-2 testing records to guide 156 categorization and were classified as described in Figure 1B and Table 2 . 157 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint 158 Diagnostic performance of antigenemia for acute Nucleocapsid antigenemia was present at higher frequency and with a higher median 160 concentration in acute COVID samples compared to samples categorized as late-presenting, convalescent, 161 pre-COVID, or same-day negative (p < 0.001 for all comparisons; Figure We analyzed the dynamics of antigen level over time in samples from the acute, late-presenting 182 and convalescent groups. The frequency of detectable nucleocapsid and antigen concentration decreased 183 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint over time following diagnosis and reported symptom onset (Figures 3A-B) . 18 samples were identified 184 from patients who were asymptomatic at the time of COVID-19 diagnosis, 5 (27.7%) of which had 185 detectable nucleocapsid antigenemia. Nucleocapsid antigen was detected more frequently (50.0%) in the 186 subset of samples available from asymptomatic patients within 3 days of their diagnosis ( Figure 3C) . Table 3) . Eighteen samples had antigenemia after more than fourteen days of 204 symptoms, of which fourteen were seropositive for both N IgG and RBG IgG, two seropositive for RBD 205 IgG only, and two were seronegative for both. Thirteen had nucleocapsid level less than 46 pg/mL while 206 the other five exceeded 700 pg/mL including both N and RBD seronegative patients and N-/RBD+ 207 sample (Supplementary Table 4, Supplementary Figures 4 & 5) . Twenty individuals with samples 208 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint categorized in the acute COVID group did not have antigenemia -ten of these were collected ten or more 209 days after symptom onset (Supplementary Table 5, Supplementary Figure 6) . were also more likely to have undetectable antigenemia. Similar trends were seen in the late-presenting 216 group except for the comparison based on IgM which was not significant (Supplementary Figure 7) . 217 218

In the acute COVID group, distribution of nucleocapsid antigen was significantly different and 220 median value was higher in samples from patients who died or required intubation within 30 days of 221 sampling compared to those who survived or did not require intubation (Figure 5A-C Evolving CDC isolation guidance during the COVID-19 pandemic reflects the difficulty of 233 objectively defining resolution of SARS-CoV-2 infection. Underlying this is the persistence of RNA 234 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint targets beyond a period during which the immunocompetent individual is reasonably believed to harbor 235

been demonstrated by viral culture in immunocompromised hosts [24] [25] [26] [27] [28] . This creates a diagnostic 237 dilemma when RT-PCR is persistently positive for weeks after diagnosis, when re-infection with SARS-238

CoV-2 is a consideration, or when encountering positive SARS-CoV-2 RT-PCR test results in an 239 asymptomatic individual without history of prior objective diagnosis or prior COVID-like illness. Our 240 data suggest assessment of nucleocapsid antigenemia may assist providers in making judgments in these 241

Further, our data compels interest in whether antigenemia may provide direct evidence of active 243 viral replication, which aid in evaluation of infectiousness or guide therapeutics at an individualized level. 244

For example, antiviral agents are not likely to benefit a patient without active SARS-CoV-2 replication. 245

Clinical trial data therefore may be confounded by failure to stratify patients according to such a marker, 246 as late presenters after cessation of viral replication would likely fail to show benefit or may even suffer 247 harm from investigatory antiviral agents. In fact, recent evidence emphasizes benefit of antivirals early in 248 infection [29] . In showing its association with acute SARS-CoV-2 infection and characterizing outliers, 249 our data suggest that nucleocapsid should be further investigated as a marker of viral activity, 250 infectiousness, and a predictor of therapeutic response. 251

Strengths of our study include a diverse cohort that is among the largest in which nucleocapsid 252 antigenemia has been quantified to date and rigorous assignment of COVID-19 status through medical 253 record review. Prior studies restricting the definition of a positive case to no more than two weeks after 254 symptom onset report sensitivities between 90.9% and 97.5% and specificities between 94. 2% and 100% 255 [15-20] (see Supplementary Table 6) , and our data are consistent with these findings. Of further interest, 256 our data revealed detectable antigen in 11 (2.1%) of the blood samples obtained in the primary serosurvey 257 even though these patients were never screened with nasopharyngeal RT-PCR testing in our healthcare 258 system. These represent likely infectious patients who may have had a missed SARS-CoV-2 diagnosis 259 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 and suggest a potential role for antigenemia screening in a population for whom blood is already being 260 sampled to complement existing infection control measures. 261

We also detected antigenemia in a small number of patients with subclinical SARS-CoV-2 262 infection. Individuals who test positive for SARS-CoV-2 without antecedent or subsequent COVID-like 263 symptoms either represent shedding of replication-competent virus during subclinical disease or 264 persistent RNA shedding following subclinical disease. While we corroborate previous findings that 265 levels of antigenemia are associated with disease severity [19, 20] , the presence of antigenemia in five 266 asymptomatic individuals with SARS-CoV-2 demonstrates that antigenemia can also be present in 267 subclinical infection. Despite the difficulty associated with identifying these cases, further investigation of 268 the prevalence of antigenemia in acute asymptomatic infection is needed to clarify its role in screening 269 broad populations. 270

This study is limited by use of a convenience sampling approach and retrospective data 271 collection. Symptom onset as recorded in the medical record can be subjective and influenced by recall 272 bias. Because of the ubiquity of community-based testing, SARS-CoV-2 diagnosis was documented prior 273 to evaluation in our healthcare system for a subset of these patients and was only known to us when 274 documented in the clinical narrative in addition to being subject to biases and imprecision. In addition, 275 nucleocapsid-specific immunoglobulin may interfere with quantitation of antigenemia in individuals who 276 have seroconverted although it is currently unknown whether total (Ig-bound and unbound) antigen or 277 free (unbound only) antigen is a more meaningful clinical indicator. The primary analysis relies on the 278 assumption that each subject is immunocompetent, that immunocompetent hosts have similar duration of 279 acute COVID-19, and that there are no other confounding factors which may result in prolonged 280 antigenemia. Recognizing these limitations, we performed a post-hoc investigation of outlier cases, which 281 facilitated hypothesis generation regarding reasons for prolonged antigenemia such as reduced renal 282 function, prolonged critical illness, and immune compromise (Supplementary Tables 1-5 & 7) . Several 283 studies have demonstrated high specificity of antigenemia by evaluation of pre-pandemic samples [15, 17, 284 20] , suggesting many false positives in our study are likely to have active infection beyond the parameters 285 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint for acute infection defined in our reference standard schema. This will be further clarified as more robust 286 comparisons to viral culture, sgRNA, RT-PCR Ct value, and respiratory antigen testing can be achieved. 287

Together our data demonstrate that nucleocapsid antigenemia is a sensitive and specific 288 biomarker of acute COVID-19 wherein COVID-19 status is defined by time since earliest positive testing 289 and symptom onset. We conclude that nucleocapsid antigenemia is a promising candidate biomarker for 290 active viral replication -the definition of which is the presence of replication-competent virus in a host -291 recognizing that the available evidence points to this being an individualized process that cannot be 292 broadly defined based on a timeline. Further prospective studies with rigorous documentation of clinical 293 course and correlation with viral culture and other potential biomarkers of viral replication are needed. 294

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 *Reflects all included samples (including multiple samples for a unique patient). CDU = clinical decision unit . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 days after earliest diagnosis are not shown. (B) Serum or plasma nucleocapsid in patients whose COVID-19 course was described as asymptomatic in clinical records. The x axis reflects time in between first known positive respiratory test and the day the blood sample used in our analysis was collected. (C) Serum or plasma nucleocapsid for individuals with positive nasopharyngeal RT-PCR on the same day as blood sample collection.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint Intubation in figures B and C includes intubation within 30 days before or after the blood sample was collected.

Individuals with severe COVID as defined by the composite of 30-day intubation or mortality are highlighted in D and E.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.23.22269354 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10. 1101 /2022 

SARS-CoV-2, SARS-CoV, and 317 MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic 318 review and meta-analysis

Characteristics of Viral Shedding Time in SARS-CoV-2 320 Infections: A Systematic Review and Meta-Analysis

Prevention CfDCa. COVID-19 Quarantine and Isolation

Prevention CfDCa. CDC Updates and Shortens Recommended Isolation and Quarantine Period 326 for General Population

Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods 328 to be a Surrogate for Replication-Competent Virus

Rethinking Covid-19 Test Sensitivity -A Strategy for 330 Containment

Frequency of Routine Testing 332 for Coronavirus Disease 2019 (COVID-19) in High-risk Healthcare Environments to Reduce 333 Outbreaks

Nucleocapsid Protein as Early Diagnostic Marker for SARS

Detection of the nucleocapsid protein of severe acute respiratory 337 syndrome coronavirus in serum: Comparison with results of other viral markers

Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and 340

Specificity Early Diagnostic Marker for SARS-COV-2 Infection

Serum 343 SARS-CoV-2 nucleocapsid antigen detection is essential for primary diagnostics of SARS-CoV-344 2-associated pneumonia. medRxiv: Cold Spring Harbor Laboratory

Quantification of SARS-CoV-2 antigen levels in the blood of patients 346 with COVID-19

Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and 348

Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe 349 Disease

Detection of SARS-CoV-2 N-antigen in blood during 351 acute COVID-19 provides a sensitive new marker and new testing alternatives

CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection. medRxiv. 355 medRxiv: Cold Spring Harbor Laboratory

N-protein presents early in blood, dried blood and 357 saliva during asymptomatic and symptomatic SARS-CoV-2 infection

Diagnostic Value of Nucleocapsid Protein in Blood for SARS-360

CoV-2 Infection

SARS-CoV-2 Nucleocapsid Plasma Antigen for 362 Diagnosis and Monitoring of COVID-19

Serum SARS-CoV-2 Antigens for the Determination of 364 COVID-19 Severity. medRxiv: Cold Spring Harbor Laboratory

Early Laboratory Diagnosis of COVID-19 by Antigen 366 Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein

Serologies for the Diagnosis of Acute COVID-19

Persistence and Evolution of SARS-CoV-2 in an 372 Immunocompromised Host

Case Study: Prolonged Infectious SARS-CoV-2 374 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Replication in a CAR-T-cell Therapy Recipient: A Case Study

Shedding of Viable SARS-CoV-2 after 379 Immunosuppressive Therapy for Cancer

Recurrent deletions in the SARS-CoV-2 spike 381 glycoprotein drive antibody escape

Early Remdesivir to Prevent Progression to Severe 383

Covid-19 in Outpatients